Poolbeg’s POLB 001 shows promise in cancer treatment
13th December 2024
Poolbeg Pharma presents promising data for POLB 001 at ASH Annual Meeting, showing potential in cancer immunotherapy-induced CRS. Learn more here.
Poolbeg Pharma presents promising data for POLB 001 at ASH Annual Meeting, showing potential in cancer immunotherapy-induced CRS. Learn more here.
Discover how Dundalk Institute of Technology’s WISDOM mentorship initiative is shaping the careers of science students, bridging academia with industry experience.
Discover how artificial intelligence is transforming drug development by streamlining data processing and enhancing predictive models for more efficient research.
The 66th ASH Annual Meeting and Exposition will be held from 7–10 December 2024, in San Diego, California, with an online component. As the most extensive event in the field
Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38
Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified
Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s
Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that it will present a poster
Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
